
==== Front
BMC Geriatr
BMC Geriatr
BMC Geriatrics
1471-2318
BioMed Central London

5371
10.1186/s12877-024-05371-w
Case Report
Serotonin syndrome caused by escitalopram in Parkinson’s disease psychosis: a case report
Wang Shan’mei
Qiu Linghe
Zhou Qin
Chen Caixia 13358119032@189.com

Wu Jianhong jianhong_wu@qq.com

https://ror.org/04mkzax54 grid.258151.a 0000 0001 0708 1323 Affiliated Mental Health Center of Jiangnan University , No. 156 QianRong Rd, Wuxi, Jiangsu, 214151 China
18 9 2024
18 9 2024
2024
24 76914 1 2024
9 9 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
Background

Serotonin syndrome and Parkinson’s disease (PD) are two diseases whose symptoms partially overlap; this poses challenges in distinguishing them in clinical practice. Early manifestations such as tremor, akathisia, diaphoresis, hypertonia and hyperreflexia are common in mild-to-moderate serotonin syndrome and can also occur in PD. Without prompt recognition and treatment, serotonin syndrome can rapidly progress, potentially leading to severe complications such as multiple organ failure within hours. Given their disparate treatment strategies, accurate clinical distinction is crucial for effective treatment. This case study explores a patient with serotonin syndrome triggered by escitalopram in the context of PD psychosis (PDP), providing insights into diagnosis and treatment planning.

Case presentation

A 75-year-old Asian woman with a one-year history of PD, a two-month history of PDP, and a six-year history of depression presented with symptoms including hyperreflexia, tremor, hypertonia, impaired level of consciousness, and inappropriate behavior following a recent one-month adjustment in medication. Initially suspected of being drug-induced parkinsonism or worsening PD, therapeutic drug monitoring revealed warning levels of escitalopram. Subsequent diagnoses confirmed serotonin syndrome. This syndrome may result from increased cortical serotonin activity at the serotonin2A receptor due to dopamine and serotonin imbalances in PDP, compounded by increased dopamine-mediated serotonin release. Additionally, being an intermediate metabolizer of cytochrome P450 enzyme 2C19, the patient experienced excessive escitalopram accumulation, exacerbating her condition.

Conclusions

This case underscores the critical need to differentiate between symptoms of serotonin syndrome and PD, particularly in manifestations like tremor and hypertonia. Careful consideration of receptor profiles in patients with PDP is essential when selecting antidepressants to mitigate the risk of serotonin syndrome.

Keywords

Parkinson’s disease psychosis
Serotonin syndrome
Escitalopram
Case report
http://dx.doi.org/10.13039/100018731 Jiangsu Hengrui Medicine No. H202139 issue-copyright-statement© BioMed Central Ltd., part of Springer Nature 2024
==== Body
pmcBackground

Serotonin syndrome is a rapidly progressing and potentially life-threatening adverse drug reaction triggered by serotoninergic medications. It arises from excessive activation of postsynaptic serotonin receptors, manifesting in symptoms affecting both the central and peripheral nervous system [1]. Typical clinical features include an altered mental state, autonomic dysfunction, and neuromuscular excitement [2]. Parkinson’s disease (PD) is a neurodegenerative disorder characterized by motor symptoms such as bradykinesia, rigidity, tremors, and changes in gait and posture reflexes [3]. Early-stage serotonin syndrome symptoms, such as tremor and hypertonia, partially overlap with PD manifestations, posing significant challenges in clinical differentiation [4]. Herein, we report the case of a patient with PD psychosis (PDP) who was undergoing treatment with escitalopram and was subsequently diagnosed with serotonin syndrome. This report highlights the differences between serotonin syndrome and PD, emphasizing the use of therapeutic drug monitoring (TDM) and genetic testing to elucidate possible pathogenic mechanisms.

Case presentation

The patient was a 75-year-old woman with a six-year history of depression and a two-month history of PDP. On July 14, 2023, she was admitted to the hospital due to visual hallucinations and inappropriate behavior. Upon admission, the patient began treatment with levodopa/benserazide 0.125 g tid and quetiapine 12.50 mg qn. Three days later (July 17), in response to recurring depressive symptoms, escitalopram 5 mg qd was added to her regimen based on her medication history. The dosage of levodopa/benserazide was gradually reduced to 0.0625 g bid and quetiapine increased to 37.5 mg qn to manage persistent hallucinations and inappropriate behavior by July 19.

After a 12-day hospitalization (July 25), the patient reported no further hallucinations but continued to exhibit impaired insight and inappropriate nighttime behavior. Consequently, the dosage of quetiapine was reduced to 25 mg qn. To address persistent depression, escitalopram was gradually increased to 20 mg qd by July 28. On August 7, levodopa/benserazide was adjusted to 0.0625 g tid for bradykinesia.

However, by day 26 (August 8), the patient had developed impaired level of consciousness and alteration in language. As a result, the dosages of quetiapine and escitalopram were reduced to 12.5 mg qn and 10 mg qd, respectively. Two days later (August 10), she exhibited apathy, a slight neck tilt, sialorrhea, and urinary incontinence. Vital signs were: blood pressure 146/80 mmHg, heart rate 89 beats/minute, respiratory rate 18 breaths/minute, and temperature 36.3 °C. A physical examination revealed hypertonia and mild tremors. During the mental status examination, the patient exhibited impaired level of consciousness, disorientation, and a lack of cooperation. Laboratory tests showed no significant abnormalities, and a head scan indicated no changes from the initial admission.

Initially diagnosed with drug-induced parkinsonism (DIP), treatment included intravenous infusions of vitamins C and B6, potassium chloride, and benzhexol 2 mg qd (Fig. 1). Despite treatment, her symptoms of hypertonia, tremors, hyperreflexia, neck stiffness, and neck tilt persisted over the next 24 h. Quetiapine levels measured 11.9 ng/ml, which was below the therapeutic range.Fig. 1 Timeline of our patient

On August 11, the dosage of benzhexol was adjusted to 1 mg tid, and escitalopram was reduced to 5 mg qd. Three days later (August 14), the patient exhibited noticeable head tilting to the right and dysphagia. Persistent symptoms included tremors, limb stiffness, hyperreflexia, and hypertonia. Consequently, the dosage of benzhexol was increased to 2 mg bid and levodopa/benserazide to 0.125 g bid (Fig. 2).Fig. 2 Medication of quetiapine, escitalopram, benzhexol and levodopa/benserazide

This situation prompted the question: could this symptoms combination—autonomic dysfunction, neuromuscular excitement, and altered mental status—indicate serotonin syndrome, despite closely resembling the PD or DIP symptoms? To explore this possibility, we conducted TDM and genetic testing of escitalopram metabolic enzymes. Surprisingly, escitalopram levels measured 171.7 ng/ml, significantly exceeding the warning threshold. Genetic testing revealed a cytochrome P450 enzyme (CYP) 2C19 polymorphism, indicating intermediate metabolism. Based on these findings, the patient received a definitive diagnosis of serotonin syndrome.

Intravenous infusion therapy was continued to expedite drug metabolism, and both escitalopram and quetiapine were promptly discontinued. By August 18, with escitalopram levels reduced to 40.1 ng/ml, the patient’s symptoms showed improvement, except for persisting hypertonia, prompting cessation of benzhexol and intravenous rehydration. By August 21, the patient had regained consciousness and resumed normal conversational abilities. Limb movement became more flexible, with relief from tremors and hyperreflexia, although muscle tension persisted, later confirmed as a symptom of PD. Over the subsequent months, levodopa/benserazide was gradually adjusted to 0.125 g qid. Muscle tension continued to improve, and the patient was discharged a few weeks after achieving stability.

Discussion and conclusions

According to Hunter’s criteria, serotonin syndrome is characterized by well-defined symptoms including clonus, agitation, diaphoresis, tremor, hyperreflexia, hypertonia and elevated temperature (Fig. 3) [2]. The severity of these symptoms varies with serotonin toxicity severity and may not consistently appear in every patient [5]. Clonus, whether inducible, spontaneous, or ocular, is a core neuromuscular feature closely associated with serotonin syndrome [6]. However, not all patients exhibit obvious clonus; mild cases may only show tremor or an altered mental state, complicating the diagnosis.Fig. 3 Well-defined symptoms of serotonin syndrome

Tremor and hypertonia can overlap with PD symptoms (Fig. 4). PD tremor, characterized by involuntary, rhythmic, alternating movements [7], typically presents as resting tremor [8]. In contrast, tremors associated with serotonin syndrome, or DIP, lack this re-emergent characteristic (Table 1). Hypertonia, an abnormal increase in muscle tone, can sometimes overshadow tremor [1, 9] and present in three forms: spasticity during passive movement, dystonia during active movement, and rigidity throughout all states of movement [10]. In serotonin syndrome, hypertonia appears as a neuromuscular excitation symptom, whereas PD-related rigidity stems from muscle weakness and impaired muscle flexibility [11]. Early-stage serotonin syndrome, especially with mild neuromuscular excitement, may not exhibit clonus, posing challenges in differentiation from PD-induced rigidity.Fig. 4 Comparison of serotonin syndrome and PD

Table 1 Different types of tremors between PD, serotonin syndrome, neuroleptic malignant syndrome (NMS), DIP, and antidepressants induced-tremor

Classification	Type of tremor	Feature	Distinguish method	
PD	resting tremor	appears when gravity is completely opposed, commonly unilateral in onset [12]	setting a new posture, such as holding hands flat. With a new posture, re-emergent tremor reappears after a few seconds, while other tremors appears immediately [13]	
re-emergent tremor	resting tremor ceases when the muscles are activated voluntarily to execute a posture, and it may be followed by delayed re-emergence of tremor when a new limb posture is sustained [14]	
Serotonin syndrome	intermittent tremor	greater in lower extremities [1]	
NMS	cogwheel tremor	lead tube rigidity in all muscle groups [15]	
DIP	essential tremor	a postural tremor and an action tremor [16, 17]	
Antidepressants induced-tremor	

To differentiate between spasticity and rigidity, a slow stretch of a muscle was performed, such as passively and slowly straightening the elbow joint from the flexed position. Spasticity does not manifest during slow stretching, whereas rigidity, characterized by continuous resistance akin to a lead pipe or cogwheel, remains consistent regardless of stretch speed. Notably, muscle symptoms in serotonin syndrome may be more prominent in the lower extremities compared to the upper extremities, providing a slight distinction in identifying these conditions (Table 2). Table 2 Different types of hypertonia between PD and serotonin syndrome

Classification	Type of hypertonia	Type of stretch reflection	Conduction path	Feature	Location	Special expression	Distinguish method	
PD	rigidity [3]	non-speed dependent	extrapyramidal system	hypertonia present in all states of passive and active movement [18]	obvious in the flexors of the neck, trunk and limbs	lead tube rigidity and cogwheel rigidity	slowly stretch a muscle	
Serotonin syndrome	spasticity (increased muscle tension caused by neurological lesions [19])	velocity-dependent hypertonia caused by upper motor neuron damage [20]	pyramidal system	muscle overactivity, hyperreflexia, clonus (rapid muscle contractions [19, 21]), clasp-knife phenomenon, flexor and extensor spasms, Babinski sign, and spastic dystonia [20].	obvious in the lower extremities [1]	clonus (inducible, spontaneous or ocular)	

Our patient presented with hypertonia, tremor, and hyperreflexia, with particularly notable hyperreflexia observed during periods of elevated escitalopram levels, a typical symptom of serotonin syndrome [9]. Despite adjustments to levodopa/benserazide dosage, the tremor did not improve, ruling out the possibility of PD-induced tremor. Based on the elevated escitalopram levels and adherence to Hunter’s criteria, the patient received a diagnosis of serotonin syndrome. Hypertonia persisted beyond the resolution of serotonin syndrome but responded favorably to increased levodopa/benserazide, suggesting inadequate management PD symptoms. Despite considering various potential causes, including DIP, NMS, and malignant syndrome in PD, our diagnostic investigations did not support these alternative diagnoses (Table 3). Table 3 Differences between PD, serotonin syndrome, NMS, DIP, and malignant syndrome in PD

	Classification	Pathogenesis	Core symptoms	Treatment	
Disease	PD	a neurodegenerative disease caused by dysfunction of the basal ganglia	bradykinesia, rigidity (hypertonia), tremor, and altered gait and postural reflexes [3]	pharmacologic approaches (typically with levodopa preparations prescribed with or without other medications) and nonpharmacologic approaches (such as exercise and physical, occupational, and speech therapies) [22]	
Adverse drug reaction	serotonin syndrome	serotonin overdose in synaptic cleft	hyperreflexia, tremor, and clonus	intravenous hydration, general symptomatic treatment, withdrawal of the serotoninergic drugs and medication (cyproheptadine)	
NMS	a neuroleptic-induced alteration of central neuroregulatory mechanisms and an abnormal reaction of predisposed skeletal muscle [23]	hyperthermia (≥ 38.5℃), bradyreflexia [15, 24], muscle ‘lead pipe’ rigidity and an elevated creatine phosphokinase concentration	general symptomatic treatment, withdrawal of the neuroleptic agents and medication (bromocriptine and dantrolene)	
DIP	imbalance between dopamine and acetylcholine in the substantia nigra striatum	tremor, muscle rigidity, bradykinesia and loss of movement	withdrawal of antipsychotics, switch to other antipsychotics and medication (benzhexol)	
Withdrawal reaction	malignant syndrome in PD	acute dopaminergic hypo-transmission in the hypothalamus, nigrostriatal system, and mesocortical dopaminergic system [25]	elevated serum creatine kinase, consciousness confusion, autonomic dysfunction, high temperature, and noticeable stiffness	intravenous hydration, external cooling, add levodopa, and medication (bromocriptine and dantrolene) [26]	

Serotonin syndrome, despite sharing similarities with other syndromes, can be readily diagnosed using Hunter’s criteria (Fig. 5, adapted from Wu et al., 2023 [27]). It is crucial for clinicians treating PD patients to be vigilant about the potential association with serotonin syndrome. Once this connection is recognized, identifying clinical features and applying Hunter’s diagnostic criteria simplifies the diagnostic process.Fig. 5 The Hunter’s decision rules of serotonin syndrome, adapted from Wu et al., 2023 [27]

The development of serotonin syndrome in our patient had the following stages: the patient experienced visual hallucinations subsequent to the PD diagnosis, indicating PDP. More than 50% of PD patients progress to PDP [28], characterized by dopamine deficiency in the substantia nigra and striatum, along with excessive cortical serotonin and midbrain marginal dopamine. This imbalance amplifies serotonin-mediated neurotransmission in the lateral temporal cortex, which is crucial for visual processing, thereby precipitating hallucinations [29]. This phenomenon likely results from toxic alpha-synuclein-containing Lewy bodies depositing in the cerebral cortex, disrupting serotonin and dopamine neurotransmission, upregulating and overstimulating cortical serotonin2A receptors, and triggering excessive dopamine release in mesolimbic circuits [30]. Simply put, PDP can be conceptualized as a serotonin-dopamine imbalance syndrome, where heightened serotonin2A or dopamine2 receptor activity, or both [30], amplify the impact of increased synaptic serotonin due to heightened serotonin2A receptor activity. Moreover, escitalopram is primarily metabolized by CYP2C19, a highly polymorphic enzyme that introduces individual variations in pharmacokinetics [27]. Our patient, identified as an intermediate metabolizer with two nonfunctional alleles (CYP2C19 *1/*2), exhibited slower escitalopram metabolism, resulting in drug accumulation. Additionally, while levodopa typically reduces brain serotonin levels, it can also enhance serotonin release and undergo decarboxylation into dopamine within serotoninergic neurons. This process involves the translocation of endogenous serotonin to synaptic clefts and receptor sites [31]. Consequently, the combination of increased serotonin receptor activity, reduced serotonin reuptake due to escitalopram overdose, and increased serotonin release from levodopa collectively elevates serotonin levels, contributing to serotonin syndrome.

For PDP patients, blocking serotonin2A receptors theoretically reduces excessive serotonin levels, restores the serotonin-dopamine balance, and alleviates visual hallucinations without exacerbating motor symptoms. Serotonin2A receptor blockers, reverse agonists, or antipsychotic drugs with serotonin2A antagonist effects are used to manage psychiatric symptoms [28]. However, in treating depression in PDP patients, up-regulation of serotonin receptors theoretically increases the risk of serotonin syndrome when using selective serotonin reuptake inhibitors.

This study represents the first comparison of neurological manifestations between PD and serotonin syndrome. Early-stage of serotonin syndrome symptoms may be obscured by PD, especially in the absence of core symptoms. Identifying symptoms such as tremors is crucial for distinguishing between PD and serotonin syndrome. Hypertonia may be more challenging to differentiate and should be assessed based on medication history and a physical examination. Core symptoms of serotonin syndrome, including hyperreflexia and clonus, facilitate rapid diagnosis when coupled with medication records, which should be closely monitored in clinical settings. TDM and genetic testing are sometimes necessary for managing serotonin syndrome effectively.

Abbreviations

NMS Neuroleptic malignant syndrome

PD Parkinson’s disease

PDP Parkinson’s disease psychosis

DIP Drug-induced parkinsonism

TDM Therapeutic drug monitoring

CYP Cytochrome P450 enzyme

Acknowledgements

Not applicable.

Authors’ contributions

JW and SW gathered the information; LQ and QZ performed the literature search; CC analyzed the data, and coordinated the case report; JW contributed to writing the first draft of the manuscript, and LQ edited and revised the manuscript. All authors read and approved the final manuscript.

Funding

The work was supported by the HENGRUI Foundation of Jiangsu Pharmaceutical Association (No. H202139).

Availability of data and materials

The datasets used and/or analyzed during the current study available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate

The patient signed an informed consent form to receive hospital care and to authorize the use of personal health information for academic purposes. The informed consent form is archived at The Affiliated Mental Health Center of Jiangnan University. Wuxi, China, together with the medical record. The study was conducted in accordance with the Declaration of Helsinki, and was approved by the Ethics Committee of The Affiliated Mental Health Center of Jiangnan University (WXMHCIRB2023LLky007).

Consent for publication

Informed consent was obtained from the patient and her legal guardian(s) for publication of clinical information, and information has been de-identified to protect anonymity. The informed consent form is archived at The Affiliated Mental Health Center of Jiangnan University. Wuxi, China, together with the medical record.

Competing interests

The authors declare no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Shan’mei Wang and Linghe Qiu contributed equally to this work.
==== Refs
References

1. Boyer EW Shannon M The serotonin syndrome N Engl J Med 2005 352 11 1112 1120 10.1056/NEJMra041867 15784664
Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352(11):1112–20.15784664
2. Dunkley EJ Isbister GK Sibbritt D Dawson AH Whyte IM The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity QJM 2003 96 9 635 642 10.1093/qjmed/hcg109 12925718
Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM. 2003;96(9):635–42.12925718
3. Ye H Robak LA Yu M Cykowski M Shulman JM Genetics and pathogenesis of Parkinson’s syndrome Annu Rev Pathol 2023 18 95 121 10.1146/annurev-pathmechdis-031521-034145 36100231
Ye H, Robak LA, Yu M, Cykowski M, Shulman JM. Genetics and pathogenesis of Parkinson’s syndrome. Annu Rev Pathol. 2023;18:95–121.36100231
4. Wang RZ Vashistha V Kaur S Houchens NW Serotonin syndrome: preventing, recognizing, and treating it Clevel Clin J Med 2016 83 11 810 817 10.3949/ccjm.83a.15129
Wang RZ, Vashistha V, Kaur S, Houchens NW. Serotonin syndrome: preventing, recognizing, and treating it. Clevel Clin J Med. 2016;83(11):810–7.
5. Mikkelsen N Damkier P Pedersen SA Serotonin syndrome-A focused review Basic Clin Pharmacol Toxicol 2023 133 2 124 129 10.1111/bcpt.13912 37309284
Mikkelsen N, Damkier P, Pedersen SA. Serotonin syndrome-A focused review. Basic Clin Pharmacol Toxicol. 2023;133(2):124–9.37309284
6. Gillman PK The serotonin syndrome and its treatment J Psychopharmacol 1999 13 1 100 109 10.1177/026988119901300111 10221364
Gillman PK. The serotonin syndrome and its treatment. J Psychopharmacol. 1999;13(1):100–9.10221364
7. Abdo WF van de Warrenburg BP Burn DJ Quinn NP Bloem BR The clinical approach to movement disorders Nat Rev Neurol 2010 6 1 29 37 10.1038/nrneurol.2009.196 20057497
Abdo WF, van de Warrenburg BP, Burn DJ, Quinn NP, Bloem BR. The clinical approach to movement disorders. Nat Rev Neurol. 2010;6(1):29–37.20057497
8. Helmich RC Hallett M Deuschl G Toni I Bloem BR Cerebral causes and consequences of parkinsonian resting tremor: a tale of two circuits? Brain 2012 135 Pt 11 3206 3226 10.1093/brain/aws023 22382359
Helmich RC, Hallett M, Deuschl G, Toni I, Bloem BR. Cerebral causes and consequences of parkinsonian resting tremor: a tale of two circuits? Brain. 2012;135(Pt 11):3206–26.22382359
9. Buckley NA Dawson AH Isbister GK Serotonin syndrome BMJ 2014 348 g1626 10.1136/bmj.g1626 24554467
Buckley NA, Dawson AH, Isbister GK. Serotonin syndrome. BMJ. 2014;348:g1626.24554467
10. Evans SH Cameron MW Burton JM Hypertonia Curr Probl Pediatr Adolesc Health Care 2017 47 7 161 166 28716516
Evans SH, Cameron MW, Burton JM. Hypertonia. Curr Probl Pediatr Adolesc Health Care. 2017;47(7):161–6.28716516
11. Monte A Magris R Nardello F Bombieri F Zamparo P Muscle shape changes in Parkinson’s disease impair function during rapid contractions Acta Physiol (Oxf) 2023 238 1 e13957 10.1111/apha.13957 36876976
Monte A, Magris R, Nardello F, Bombieri F, Zamparo P. Muscle shape changes in Parkinson’s disease impair function during rapid contractions. Acta Physiol (Oxf). 2023;238(1):e13957.36876976
12. Leodori G Belvisi D De Bartolo MI Fabbrini A Costanzo M Vial F Conte A Hallett M Berardelli A Re-emergent Tremor in Parkinson’s disease: the role of the motor cortex Mov Disord 2020 35 6 1002 1011 10.1002/mds.28022 32175656
Leodori G, Belvisi D, De Bartolo MI, Fabbrini A, Costanzo M, Vial F, Conte A, Hallett M, Berardelli A. Re-emergent Tremor in Parkinson’s disease: the role of the motor cortex. Mov Disord. 2020;35(6):1002–11.32175656
13. Jankovic J Schwartz KS Ondo W Re-emergent tremor of Parkinson’s disease J Neurol Neurosurg Psychiatry 1999 67 5 646 650 10.1136/jnnp.67.5.646 10519872
Jankovic J, Schwartz KS, Ondo W. Re-emergent tremor of Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1999;67(5):646–50.10519872
14. Bhatia KP Bain P Bajaj N Elble RJ Hallett M Louis ED Raethjen J Stamelou M Testa CM Deuschl G Consensus Statement on the classification of tremors. from the task force on tremor of the International Parkinson and Movement Disorder Society Mov Disord 2018 33 1 75 87 10.1002/mds.27121 29193359
Bhatia KP, Bain P, Bajaj N, Elble RJ, Hallett M, Louis ED, Raethjen J, Stamelou M, Testa CM, Deuschl G. Consensus Statement on the classification of tremors. from the task force on tremor of the International Parkinson and Movement Disorder Society. Mov Disord. 2018;33(1):75–87.29193359
15. Caroff SN Mann SC Neuroleptic malignant syndrome Med Clin North Am 1993 77 1 185 202 10.1016/S0025-7125(16)30278-4 8093494
Caroff SN, Mann SC. Neuroleptic malignant syndrome. Med Clin North Am. 1993;77(1):185–202.8093494
16. Friedman JH Movement disorders induced by psychiatric drugs that do not block dopamine receptors Parkinsonism Relat Disord 2020 79 60 64 10.1016/j.parkreldis.2020.08.031 32871538
Friedman JH. Movement disorders induced by psychiatric drugs that do not block dopamine receptors. Parkinsonism Relat Disord. 2020;79:60–4.32871538
17. Arbaizar B Gómez-Acebo I Llorca J Postural induced-tremor in psychiatry Psychiatry Clin Neurosci 2008 62 6 638 645 10.1111/j.1440-1819.2008.01877.x 19067999
Arbaizar B, Gómez-Acebo I, Llorca J. Postural induced-tremor in psychiatry. Psychiatry Clin Neurosci. 2008;62(6):638–45.19067999
18. Sanger TD Delgado MR Gaebler-Spira D Hallett M Mink JW Classification and definition of disorders causing hypertonia in childhood Pediatrics 2003 111 1 e89 97 10.1542/peds.111.1.e89 12509602
Sanger TD, Delgado MR, Gaebler-Spira D, Hallett M, Mink JW. Classification and definition of disorders causing hypertonia in childhood. Pediatrics. 2003;111(1):e89-97.12509602
19. Wieters F Weiss Lucas C Gruhn M Büschges A Fink GR Aswendt M Introduction to spasticity and related mouse models Exp Neurol 2021 335 113491 10.1016/j.expneurol.2020.113491 33007294
Wieters F, Weiss Lucas C, Gruhn M, Büschges A, Fink GR, Aswendt M. Introduction to spasticity and related mouse models. Exp Neurol. 2021;335:113491.33007294
20 Sheean G The pathophysiology of spasticity Eur J Neurol 2002 9 Suppl 1 3 9 10.1046/j.1468-1331.2002.0090s1003.x 11918643
Sheean G. The pathophysiology of spasticity. Eur J Neurol. 2002;9 Suppl 1:3–9. dicussion 53-61.11918643
21. Gracies JM Bayle N Vinti M Alkandari S Vu P Loche CM Colas C Five-step clinical assessment in spastic paresis Eur J Phys Rehabil Med 2010 46 3 411 421 20927007
Gracies JM, Bayle N, Vinti M, Alkandari S, Vu P, Loche CM, Colas C. Five-step clinical assessment in spastic paresis. Eur J Phys Rehabil Med. 2010;46(3):411–21.20927007
22. Armstrong MJ Okun MS Diagnosis and treatment of Parkinson disease: a review JAMA 2020 323 6 548 560 10.1001/jama.2019.22360 32044947
Armstrong MJ, Okun MS. Diagnosis and treatment of Parkinson disease: a review. JAMA. 2020;323(6):548–60.32044947
23. Adnet P Lestavel P Krivosic-Horber R Neuroleptic malignant syndrome Br J Anaesth 2000 85 1 129 135 10.1093/bja/85.1.129 10928001
Adnet P, Lestavel P, Krivosic-Horber R. Neuroleptic malignant syndrome. Br J Anaesth. 2000;85(1):129–35.10928001
24. Prakash S A diagnostic confusion between Serotonin syndrome and Neuroleptic malignant syndrome Am J Emerg Med 2021 43 272 273 10.1016/j.ajem.2020.06.046 33008703
Prakash S. A diagnostic confusion between Serotonin syndrome and Neuroleptic malignant syndrome. Am J Emerg Med. 2021;43:272–3.33008703
25. Mizuno Y Takubo H Mizuta E Kuno S Malignant syndrome in Parkinson’s disease: concept and review of the literature Parkinsonism Relat Disord 2003 9 Suppl 1 S3 9 10.1016/S1353-8020(02)00125-6 12735909
Mizuno Y, Takubo H, Mizuta E, Kuno S. Malignant syndrome in Parkinson’s disease: concept and review of the literature. Parkinsonism Relat Disord. 2003;9(Suppl 1):S3-9.12735909
26. Yamawaki Y Ogawa N Successful treatment of levodopa-induced neuroleptic malignant syndrome (NMS) and disseminated intravascular coagulation (DIC) in a patient with Parkinson’s disease Intern Med 1992 31 11 1298 1302 10.2169/internalmedicine.31.1298 1295627
Yamawaki Y, Ogawa N. Successful treatment of levodopa-induced neuroleptic malignant syndrome (NMS) and disseminated intravascular coagulation (DIC) in a patient with Parkinson’s disease. Intern Med. 1992;31(11):1298–302.1295627
27. Wu J Yu J Qu K Yin J Zhu C Liu X Serotonin syndrome caused by a CYP2C19-mediated interaction between low-dose escitalopram and clopidogrel: a case report Front Psych 2023 14 1257984 10.3389/fpsyt.2023.1257984
Wu J, Yu J, Qu K, Yin J, Zhu C, Liu X. Serotonin syndrome caused by a CYP2C19-mediated interaction between low-dose escitalopram and clopidogrel: a case report. Front Psych. 2023;14:1257984.
28. Cummings J Isaacson S Mills R Williams H Chi-Burris K Corbett A Dhall R Ballard C Pimavanserin for patients with Parkinson’s disease psychosis: a randomised, placebo-controlled phase 3 trial Lancet 2014 383 9916 533 540 10.1016/S0140-6736(13)62106-6 24183563
Cummings J, Isaacson S, Mills R, Williams H, Chi-Burris K, Corbett A, Dhall R, Ballard C. Pimavanserin for patients with Parkinson’s disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet. 2014;383(9916):533–40.24183563
29. Huot P Johnston TH Darr T Hazrati LN Visanji NP Pires D Brotchie JM Fox SH Increased 5-HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations Mov Disord 2010 25 10 1399 1408 10.1002/mds.23083 20629135
Huot P, Johnston TH, Darr T, Hazrati LN, Visanji NP, Pires D, Brotchie JM, Fox SH. Increased 5-HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations. Mov Disord. 2010;25(10):1399–408.20629135
30. Stahl SM Parkinson's disease psychosis as a serotonin-dopamine imbalance syndrome CNS Spectr 2016 21 5 355 359 10.1017/S1092852916000602 27686027
Stahl SM. Parkinson’s disease psychosis as a serotonin-dopamine imbalance syndrome. CNS Spectr. 2016;21(5):355–9.27686027
31. Everett GM Borcherding JW L-dopa: effect on concentrations of dopamine, norepinephrine, and serotonin in brains of mice Science 1970 168 3933 849 850 10.1126/science.168.3933.849 17768920
Everett GM, Borcherding JW. L-dopa: effect on concentrations of dopamine, norepinephrine, and serotonin in brains of mice. Science. 1970;168(3933):849–50.17768920
